New Abbott Partnership Aims to Bring ‘Artificial Pancreas” to European Market
May 2, 2022
Abbott has partnered with Camdiab and Ypsomed to bring their novel electronic diabetes management system to Europe. The alliance’s “artificial pancreas system” combines Abbott’s Freestyle Libre 3 wearable sensor with Ypsomed’s insulin pump and Camdiab’s mobile app. Working in concert, the three track blood glucose levels in real-time and deliver insulin as needed.
According to Phil Taylor of PharmaPhorum, “CamDiab and Ypsomed have been working together on a smartphone-based AID since March, bundling the CamAPS FX app with Ypsomed’s mylife YpsoPump in an offering that has already started to roll out in some European countries. Adding Abbott to the alliance closes the circle, moving close to an entirely automated system for people with diabetes.”
To read more, click here.
(Source: PharmaPhorum, April 28th, 2022)